Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Niagen Bioscience, Inc. - Common Stock (NQ:NAGE)

5.175 +0.235 (+4.76%)
Streaming Delayed Price Updated: 3:05 PM EST, Mar 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,470,294
Open 5.690
Bid (Size) 5.180 (700)
Ask (Size) 5.190 (300)
Prev. Close 4.940
Today's Range 4.980 - 5.780
52wk Range 4.725 - 14.69
Shares Outstanding 68,196,526
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Niagen Bioscience Inc (NASDAQ:NAGE) Reports Q4 2025 Revenue Beat and Mixed Earnings ↗
Via Chartmill
News headline image
Niagen Bioscience (NAGE) Earnings Transcript ↗
Niagen Bioscience (NAGE) Earnings Transcript 
Via The Motley Fool
Topics Intellectual Property

Performance

YTD
-17.2%
-17.2%
1 Month
-15.0%
-15.0%
3 Month
-20.8%
-20.8%
6 Month
-46.5%
-46.5%
1 Year
-33.1%
-33.1%

More News

Read More
Get insights into the top gainers and losers of Wednesday's after-hours session. ↗
Via Chartmill
News headline image
Niagen Bioscience Reports 30% Year-Over-Year Net Sales Increase to $129.4 million, 103% Net Income Increase to $17.4 million or $0.22 Basic EPS in 2025
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Earnings Scheduled For November 4, 2025 ↗
Via Benzinga
News headline image
Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone
Via FinancialNewsMedia
News headline image
Niagen Bioscience to Streamline and Focus its Operations with the Sale of ChromaDex Reference Standards Business to LGC in All-Cash Transaction
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience Secures New U.S. Patent Covering Intravenous and Injection Formulations and Methods of Use for Nicotinamide Riboside (NR), Niagen®
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience is the Premiere Sponsor of the Inaugural “NAD for Health: Opportunities & Challenges” Conference Hosted by the University of Copenhagen
From Niagen Bioscience, Inc.
Via Business Wire
News headline image
Niagen Bioscience to Report Fourth Quarter and Full Year 2025 Financial Results on Wednesday, March 4, 2026
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Functional Wellness Stocks Explode as $179 Billion Beverage Market Ditches Sugar for Science
From Equity Insider
Via GlobeNewswire
News headline image
Niagen Bioscience Expands HSA/FSA Access for Tru Niagen®, the Leading NAD+ Supplement in the U.S.*
From Niagen Bioscience, Inc
Via Business Wire
News headline image
THE FOCUS DOCTRINE: 5 Assets Securing the 2026 Biological Choke Point
From USA News Group
Via GlobeNewswire
News headline image
Niagen Bioscience Acquires Existing Core Nicotinamide Riboside (NR) Patent Portfolio from Queen’s University Belfast
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience Launches Tru Niagen® Beauty — The First NAD+ Skincare Supplement in the U.S. Featuring Niagen® (Patented Nicotinamide Riboside)
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience Announces $10 Million Share Repurchase Program
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience Announces Results from First-Ever Randomized Controlled Trial Exploring Niagen (Patented Nicotinamide Riboside, NR) Supplementation in Long COVID
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience, Inc. Reports Third Quarter 2025 Financial Results and Reaffirms Increased Full Year Outlook
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience Increases Full Year 2025 Net Sales Outlook to 25% to 30% Year-Over-Year Growth
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience's Pharmaceutical-Grade Niagen™ IV and Injections Now Available at over 50 iCRYO Clinics and More than 900 Total Clinics Nationwide
From Niagen Bioscience, Inc
Via Business Wire
News headline image
AboutNADⓇ Debuts as the Leading Online Resource for Scientific Advancements in NAD+
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Breaking Down Niagen Bioscience: 4 Analysts Share Their Views ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
Via Benzinga
News headline image
Niagen NAGE Q2 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings

Frequently Asked Questions

Is Niagen Bioscience, Inc. - Common Stock publicly traded?
Yes, Niagen Bioscience, Inc. - Common Stock is publicly traded.
What exchange does Niagen Bioscience, Inc. - Common Stock trade on?
Niagen Bioscience, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Niagen Bioscience, Inc. - Common Stock?
The ticker symbol for Niagen Bioscience, Inc. - Common Stock is NAGE on the Nasdaq Stock Market
What is the current price of Niagen Bioscience, Inc. - Common Stock?
The current price of Niagen Bioscience, Inc. - Common Stock is 5.175
When was Niagen Bioscience, Inc. - Common Stock last traded?
The last trade of Niagen Bioscience, Inc. - Common Stock was at 03/05/26 03:05 PM ET
What is the market capitalization of Niagen Bioscience, Inc. - Common Stock?
The market capitalization of Niagen Bioscience, Inc. - Common Stock is 352.92M
How many shares of Niagen Bioscience, Inc. - Common Stock are outstanding?
Niagen Bioscience, Inc. - Common Stock has 353M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.